VYNE Therapeutics Inc.
VYNE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $169 | $69 | $202 | $84 |
| % Growth | 144.9% | -65.8% | 140.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $169 | $69 | $202 | $84 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $5,256 | $4,881 | $6,124 | $9,684 |
| G&A Expenses | $0 | $2,730 | $3,275 | $3,170 |
| SG&A Expenses | $2,705 | $2,730 | $3,275 | $3,170 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $7,961 | $7,611 | $9,399 | $12,854 |
| Operating Income | -$7,792 | -$7,542 | -$9,197 | -$12,770 |
| % Margin | -4,610.7% | -10,930.4% | -4,553% | -15,202.4% |
| Other Income/Exp. Net | $366 | $1,795 | $594 | $760 |
| Pre-Tax Income | -$7,426 | -$5,747 | -$8,603 | -$12,010 |
| Tax Expense | $0 | $0 | $0 | $4 |
| Net Income | -$7,280 | -$5,755 | -$8,611 | -$12,022 |
| % Margin | -4,307.7% | -8,340.6% | -4,262.9% | -14,311.9% |
| EPS | -0.17 | -0.13 | -0.2 | -0.28 |
| % Growth | -30.8% | 35% | 28.6% | – |
| EPS Diluted | -0.17 | -0.13 | -0.2 | -0.28 |
| Weighted Avg Shares Out | 42,745 | 42,759 | 42,673 | 42,588 |
| Weighted Avg Shares Out Dil | 42,745 | 42,759 | 42,673 | 42,588 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $6 | $6 | $6 | $0 |
| EBITDA | -$7,420 | -$7,536 | -$9,191 | -$12,770 |
| % Margin | -4,390.5% | -10,921.7% | -4,550% | -15,202.4% |